

INTERIM REPORT

Q1 2023

THE POWER
OF PRECISION.
FOR EVERY
ONCOLOGIST.
TODAY.

2curex

HIGHLIGHTS AND KEY FIGURES

EXECUTING ON OUR PLANS

Q1 2023 has been a promising start for us at 2cureX. We generated revenue of KSEK 794 from primarily grants, tested 18 patient samples, and expanded our commercial pipeline by adding 26 new hospitals, bringing the total to over 170. The IGNITE program also grew, enrolling three more hospitals adding up to a total of 27. Our efforts have paid off.

Geographically, we focused on training our newly appointed distributors in Switzerland and Austria. To broaden our reach we aim to expand into five additional European markets, achieving a total of 25 countries by the end of 2023.

Grants continue to play an important role in our success. We received (a 1.0 million EUR grant) to co-develop an automated system for handling 3D-micro-tumors, advancing the adoption of our IndiTreat® test system. Another grant of 1.5 million DKK supports the development of IndiTreat® Neo, benefitting patients with early-stage colorectal cancer.

Passing the ISO 13485 audit and preparing for IVD-R compliance ensures our commitment to quality. Our updated Specimen Collection Set enhances preservation and ease of shipment, aligning with new regulations.

With progress in product development, commercial expansion, and regulatory adaptation, we are optimistic about 2023. Our motivated team is confident in achieving our goals, making this a pivotal year for 2cureX. We sincerely appreciate your continued support.

FINANCIAL HIGHLIGHTS


The financial development is in line with our plans and expectations, and with a cash position of SEK 34.8 million at the end of Q1 2023, our capital resources can support the current activities and growth plans into Q2 2024.

(KSEK)	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Net sales	13	0	90
Other operating income	781	434	3 279
Profit before tax	-7 575	-7 897	-29 770
Earnings per share (SEK)*	-0,43	-0,45	-1,69
Equity ratio**	92%	96%	90%
Cash and bank	34 829	63 348	44 894
Average number of shares	17 602 916	17 513 876	17 580 961
No. of shares by the end of the period	17 602 916	17 602 916	17 602 916

*Earnings per share: Profit for the period divided by the average number of shares.

**Equity ratio: Shareholder's equity divided by total capital.

HIGHLIGHTS IN Q1 2023



FOR MORE INFORMATION PLEASE CONTACT:

Fernando Andreu, CEO
Mail: fa@2curex.com
Mobile: +45 2279 5399

Ole Thastrup, CSO
Mail: ot@2curex.com
Mobile: +45 2211 5399

www.2curex.com



A GOOD START

In Q1 2023, we generated revenue of KSEK 781 from different grants. We received and tested 18 patient samples and added 26 more hospitals to our commercial pipeline which includes now more than 170 hospitals. The IGNITE program has added 3 hospitals adding up to a total of 27. All in all, it has been a good start to the year.

COMMERCIAL ROLLOUT

At the end of Q1 2023, we have more than 170 potential customers in our commercial pipeline. This is 26 more than we had in the previous quarter and is the result of the tireless work that our distributors and direct sales teams have been doing. 27 of these hospitals are already enrolled in the “early access” IGNITE program, which is 3 more than Q4 2022 and 19 more compared to Q1 2022.

We expected to receive 25 patient samples in Q1 2023, and we received 18. Some of the existing IGNITE sites took longer than expected to send them, due to internal alignments and processes, but we are confident that we can close the gap in Q2 2023, as more of the 27 IGNITE sites start sending samples.

In terms of our geographic coverage, the focus in Q1 2023 was on getting the newly appointed distributor in Switzerland and Austria trained and ready to start. Our 2023 goal is to add 5 new European markets to a total geographical reach of 25 countries.

THE IMPORTANCE OF GRANTS

Historically 2cureX has been very successful in attracting innovation and research grants, which is very relevant not only financially, but also as a recognition of the level of science and technology that we are developing.

In Q1 2023 2cureX was awarded, together with its technology partners, Hahn-Schickard Institute and the Department of Microsystems Engineering (“IMTEK”) at the University of Freiburg, a 1 million EUR grant from the German Federal Ministry of Education and Research to continue the co-development of an automated system for handling of 3D-micro-tumors (tumoroids) using 2cureX’s IndiTreat® test system. This grant followed a previous BMBF grant (ADAPT) of 0.94 million EUR that was awarded in 2020.

The grant will be used to add new features to the present

prototype, including advanced AI, and will result in the automation of the IndiTreat® test, opening the door to the geographic expansion into the Asian and American markets and accelerating the adoption of the technology by hospitals. A second grant of 1.5 million DKK was awarded by the Danish Innovation Fund Denmark, to support the development of IndiTreat® Neo, a new product that will support therapy decision-making for patients in earlier stages of colorectal cancer.

With these new awards and the grants that we already had, we have reached our goal of generating 3M SEK in revenues from grants.

ISO 13485 AND IVD-R READINESS

In March we passed the annual audit of our Quality Management System, that is certified under ISO13485 (a requirement for manufacturers of Medical Devices). The focus was on the IVD-R readiness of our processes and systems and the outcome was very satisfactory – for details on the IVD-R requirements and its impact at 2cureX, please see our [Annual Report 2022](#).

Also in March, we launched an updated version of our Specimen Collection Set – the product hospitals use to ship patient samples to our labs in Copenhagen. This



update was a step towards the CE-Marking of the Specimen Collection Set under the new IVD Regulation (IVD-R), a milestone expected to be achieved within Q2 2023, but also included improvements compared to the previous one, such as an enhanced preservation of living tumoral cells, a smaller footprint for easier shipment and storage, and the implementation of the new IndiTreat® logo and design.

LOOKING AT 2023 WITH OPTIMISM

Overall, we are very satisfied with the start of this year. We are making progress on all fronts – product and technology development, commercial rollout and product uptake, and adaptation to the new European regulatory framework – while keeping our costs under tight control.

With a cash position of SEK 34.8 million by the end of Q1 2023, we are sufficiently capitalized to fund ongoing activities into Q2 2024, and we maintain our commercial expectations for 2023 with revenue of SEK 6m, IndiTreat® rollout in 25 countries, and 500 samples tested.

Our team is highly motivated, and we are therefore confident that our 2023 goals are within reach, and this will be a very important year for 2cureX. Thanks again for your continued support.

Fernando Andreu, CEO

May 25, 2023

2CUREX IN BRIEF

The key product of 2cureX is the IndiTreat® test portfolio, which allows the physician to identify the most efficient medical treatment for a particular cancer patient.

For more details see 2cureX's website at www.2curex.com



A UNIQUE COMMERCIAL PIPELINE

The number of hospitals with ongoing IndiTreat® discussions keeps growing. Together with our distributors, we have now more than 170 hospitals across 20 countries in which the IndiTreat® tests have been presented and are being considered by the relevant stakeholders – a 17% increase compared to the previous quarter. These IndiTreat® discussions are at different degrees of maturity but 27 of these hospitals are already enrolled in the IGNITE program. This healthy pipeline makes us confident that, although the internal decision-making processes in the hospitals are long, the commercial rollout of IndiTreat® is on track.

MORE THAN 170 HOSPITALS IN THE PIPELINE

The process between an oncologist getting to know IndiTreat® for the first time and the hospital making a purchasing decision is long and complex. Like in any business-to-business environment, there are multiple stakeholders involved in the decision making. There are formal product assessment steps, and the purchasing processes are formalized and tightly controlled.


In these circumstances, it is important to keep track of the “pipeline” of customers and potential customers that the company has, and to make sure that the potential customers are moving forward over time. At 2cureX we have defined seven “stations” that a customer will transit, from the first one (being introduced to IndiTreat® for the first time) to the seventh (the recurrent purchase of the test).

At the end of Q1 2023, we have more than 170 potential customers in different “stations” (meaning in different degrees of maturity in the process). This is 26 more than we had in the previous quarter, a 17% increase that shows the activity that our distributors and direct sales teams are conducting across the 20 countries where we are present. 27 of these hospitals – compared to 8 hospitals in Q1 2022 – are already enrolled in the IGNITE program that allows them to assess the value of IndiTreat® in real-life conditions. Such a pipeline is an asset no other company in this field has, that we grow and mature through our direct and indirect sales teams.

SAMPLE UPTAKE SLOWER THAN PLANNED

Our goal of receiving 500 patient samples by the end of 2023 is not evenly spread by quarters. In Q1 2023 we expected to receive 25 samples while in Q4 we expect 200. This breakdown reflects the expected transition of customers through the pipeline, and the fact that once they sign an IGNITE agreement, there’s still some internal alignment work to do, and some training, before they start sending samples.

In Q1 2023 we received 18 samples, which is below expectations, as some existing IGNITE sites took longer than expected to send them due to internal alignments and processes. Our focus in Q2 2023 is to activate all the hospitals that are already in IGNITE, in order to achieve the 100 samples that we have in the plan. For the end of the year, we maintain the goal of testing 500 patient samples.



2CUREX "SEVEN-STATIONS"




SWITZERLAND AND AUSTRIA ARE UP AND RUNNING

In Q1 2023 our focus was on getting the newly appointed distributor in Switzerland and Austria up and running, as well as supporting the rest of existing distributors in their discussions with customers. Consequently, we did not add any new territory in this quarter.

In the last two years we have grown from having operations in 5 countries to being present in 20 countries. We currently cover a population of approximately 365 million people, which represents approximately 250,000 new CRC cases every year.

Our priority in 2023 is not adding many more countries to our territories, but covering selected relevant markets in Europe that are still missing – growing the number from 20 to 25.

GRAPHICS OF 2CUREX FOOTPRINT BY Q1 2023:



Home market - Direct

Partnerships in place

2CUREX WELCOMES THE NEW UNIFIED PATENT COURT SYSTEM

A new pan-European patent system will enter into force June 1, 2023 and could very well increase the value of the 2cureX patent portfolio

2cureX has a strong patent portfolio protecting the Indi-Treat® technology. The patents are granted in major markets including Europe and the US.

Filing, prosecution and defending European patents has been a very complex task as the patent holder had to do these proceedings in each of the individual European countries. In the US there is a single system for applying and granting of patents and even more important a robust system for enforcing the patents with a unified patent court system.

The new European patent system consists of Unitary Patents (UP) and a Unified Patent Court (UPC). The UP system will reduce complexity and costs for obtaining new patents if protection is wanted in several European countries.

The UPC will have jurisdiction over all participating EU member states, presently 17 of 27 EU states. The main aim of UPC is to create a single and specialized patent court that provides high-quality, consistent decisions across Europe. UPC will have a number of advantages over the existing system of national courts. One key benefit of this is that UPC will provide a single forum for patent disputes across Europe and a specialized court system with expertise in patent law. This will help to reduce costs and complexities associated with litigating patent disputes in multiple jurisdictions.

It will also help to ensure that patent disputes are decided consistently and according to a common set of rules across Europe.

The creation of UPC has been a very long process, dating back several decades with serious discussion launched in the 2000s. The UP and UPC system that now is being implemented is a major step forward for patent law in Europe.

The system will decrease international complexity and help innovative companies to prosecute and defend their patent estate.

2cureX is an international company that presently distributes our products in 20 different European countries and has plans of moving to territories outside Europe. Our intellectual protection of our base technology IndiTreat® is key to our success in delivering individualized cancer treatment to hospitals in a multitude of countries. With the increased interest in functional drug sensitivity testing, it will be easier to defend our patent portfolio and thereby the success of 2cureX.

It is anticipated that strong patents will increase in value, as is seen in the US, as it will be easier for the patentees to defend their patents in case of infringement.

“The Unitary Patent and Unified Patent Court system represents an important simplification of the European patent system – I firmly believe that companies, with strong patent portfolios, covering multiple European countries will clearly benefit from the new system !”

Louise Aagaard

European Patent Attorney, Partner HØIBERG, European Patent Attorneys

FINANCIAL PERFORMANCE IN Q1 2023

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website (www.2cureX.com).

NET SALES AND OPERATING INCOME

Net sales for the first quarter of 2023 amounted to 13 KSEK (0 KSEK). Other operating income for the first quarter amounted to 781 KSEK (434 KSEK) all deriving from our current grants.

FINANCIAL DEVELOPMENT

The result for the first quarter of 2023 amounted to -7 575 KSEK (-7 897 KSEK). The result for the period is a result of our continued efforts to build the market awareness of our IndiTreat® technology, and commercial efforts to market IndiTreat®. Our personnel costs (17 employees) constitutes 70% of the total operating expenses.

LIQUIDITY

The Group's cash and cash equivalents amounted to 34 829 KSEK (63 348 KSEK) as of March 31, 2023. Cash flow amounted to -10 295 KSEK (-9 710 KSEK). Cash flow from operating activities in the first quarter of 2023 amounted to -10 295 KSEK (-9 710 KSEK). The monthly average operational expenses are approximately 3.2 MSEK, which is in line with the expectations.

2cureX is sufficiently capitalized to fund ongoing activities into Q2 2024. The two grants awarded during Q1 2023 will have a positive effect in the coming quarters and we are continuously working on multiple fronts to improve our cash position, not only to extend our runway but also to accelerate our development plans. Several options are evaluated both M&A, partnerships, dilutive and non-dilutive funding instruments or hybrids.

SOLIDITY

The Group's equity ratio as of March 31, 2023 amounted to 92 percent (96).

THE SHARE

There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of March 31, 2023, the number

of shares amounted to 17 602 916 (17 602 916). The average number of shares during the first quarter of 2023 amounted to 17 602 916 (17 513 876).

WARRANT PROGRAM FOR EMPLOYEES AND BOARD MEMBERS

The extra general meeting on November 5, 2020 resolved to establish a warrant program for three new board members. The warrant program totalling 120,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from October 1, 2023 up to and including December 31, 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on November 5, 2020.

Upon full exercise of the issued warrants, the share capital would increase by 12,000 SEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc.

The Annual General Meeting on May 27, 2021 established a Series 2021/24 warrant program for the Group's CEO totalling 700 000 warrants. Today this carries the right to subscribe for newly issued shares in 2cureX AB in the period April 1, 2023 to June 30, 2023 (233 333 warrants) and April 1, 2024 to June 30, 2024 (233 334 warrants).

The extra general meeting on August 8, 2022 resolved to establish a warrant program for a new board member. The warrant program totaling 40,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from August 8, 2026 up to and including October 31, 2026. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on August 8, 2022. Upon full exercise of the issued warrants, the share capital would increase by 4,000 SEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc.

The Group's result for Q1 2023 has been impacted by costs in the amount of 208 KSEK (367 KSEK) in the form of personnel costs.

**POLICIES FOR THE PREPARATION
OF THE INTERIM FINANCIAL REPORT**

2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

AUDITORS' REVIEW


This interim report has not been reviewed by the Company's auditors.

CORPORATE GOVERNANCE

The 2cureX group consists of a holding company, 2cureX AB (publ) (Sweden) that is listed at Nasdaq First North Growth Market, and two operational companies 2cureX A/S (Denmark) and 2cureX GmbH (Germany). 2cureX AB and 2cureX A/S have the same Board of Directors who has the overall responsibility of the governance structure for the 2cureX group.

Corporate governance is linked to compliance with Nasdaq First North Growth Market Rulebook and laws and regulations relevant for 2cureX.

Key aspects of the governance structure relate to shareholder's meetings, Article of Association, the composition of the Board of Director's and Board's annual wheel. The board of Directors has implemented relevant policies and procedures for 2cureX.



BOARD OF DIRECTORS



POVL-ANDRÉ BENDZ

*Chairman of 2cureX AB
and 2cureX A/S*



MICHAEL SCHAEFER

*Board member of 2cureX AB
and 2cureX A/S*



OLE THASTRUP

*Board member and CSO
of 2cureX AB and 2cureX A/S*



CAMILLA HUSE BONDEESSON

*Board Member of 2cureX AB
and 2cureX A/S*



MICHEL KLIMKEIT

*Board member of 2cureX AB
and 2cureX A/S*

CLINICAL ADVISORY BOARD



DR. JOHN L. MARSHALL

*MD is Chief, Hematology and
Oncology at Georgetown
University Hospital, and
Professor of Medicine and
Oncology at Georgetown
University in Washington D.C.*



**DR. JESUS GARCIA-
FONCILLAS**

*MD PhD is currently the
Director of the University
Cancer Institute and the
Department of Oncology
at the University Hospital
"Fundacion Jimenez Diaz"
in Spain.*



DR. ANDREW BEGGS

*is currently Professor of Cancer
Genetics & Surgery at the
Institute of Cancer and
Genomic Sciences and Co-
Lead of Molecular Oncology,
Pathology and Genetics,
University of Birmingham, UK.*

MANAGEMENT



FERNANDO ANDREU
CEO



KENNETH G. JOHANSEN
CFO



OLE THASTRUP
CSO and Deputy CEO



RAPHAEL GRUBER
Medical Director



GRITH HAGEL
VP Innovation and Technology
Development



JÜRGEN KUPPER
Managing Director
(2cureX GmbH)



JESPER FLOYD KRISTIANSEN
VP Business Development
Europe



MARK GRAY
Director of Communications



MANUEL FERNANDEZ
Director Quality & Regulatory



TABEA STURMHEIT
Director of Research



JACOB THASTRUP
Director of Product
Development

FINANCIAL CALENDAR

The Company prepares and publishes a financial report for each fiscal quarter. Upcoming reports are planned to be released as follows:

- Annual General Meeting 25/5-2023
- Interim Report Q2, 2022 24/8-2023
- Interim Report Q3, 2022 23/11-2023
- Interim Report Q4, 2022 22/2-2024
- Annual report 2023 18/4-2024



DELIVERY OF INTERIM REPORT

Landskrona, May 25, 2023 2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz
Chairman of the Board

Michael Schaefer
Member of the Board

Camilla Huse Bondesson
Member of the Board


Michel Klimkeit
Member of the Board

Ole Thastrup
Member of the Board and CSO

Fernando Andreu
CEO

CERTIFIED ADVISER
Redeye AB

FINANCIAL OVERVIEW



FINANCIAL OVERVIEW

THE GROUP

SUMMARY OF INCOME STATEMENT –THE GROUP (KSEK)	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Operating income			
Net sales	13	0	90
Other operating income	781	434	3 279
Total operating income	794	434	3 369
Operating expenses			
Other external expenses	-2 757	-3 300	-12 384
Personnel costs	-6 410	-5 147	-22 807
Depreciation of tangible fixed assets	-74	-74	-311
Total operating expenses	-9 241	-8 521	-35 502
Operating profit	-8 447	-8 087	-32 133
Financial posts	872	190	2 363
Profit before tax	-7 575	-7 897	-29 770
Tax ²⁾	0	0	0
The result of the period	-7 575	-7 897	-29 770
Earnings per share (SEK)	-0,43	-0,45	-1,69
Average number of shares	17 602 916	17 513 876	17 580 961
No. of shares at the end of the period	17 602 916	17 602 916	17 602 916

²⁾ This post refers to tax relief in subsidiaries regarding R&D work.

SUMMARY OF BALANCE SHEET – THE GROUP (KSEK)	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Assets			
Fixed assets			
Tangible fixed assets	941	626	993
Total fixed assets	941	626	993
Current assets			
Receivables	2 810	5 659	1 770
Cash and bank balances	34 829	63 348	44 894
Total current assets	37 639	69 007	46 664
Total assets	38 580	69 633	47 657
Equity and liabilities			
Equity			
Share capital	1 760	1 760	1 760
Ongoing share issue	0	0	0
Other contributed capital	107 664	111 684	107 664
Other equity	-66 171	-16 586	-36 620
The result of the period	-7 575	-766	-29 770
Total equity	35 678	99 272	43 034
Current liabilities			
Short-term liabilities ²⁾	2 904	2 887	4 623
Total short-term liabilities	2 904	2 887	4 623
Total equity and liabilities	38 580	69 633	47 657

SUMMARY OF CASH FLOW – THE GROUP (KSEK)	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Cash flow from operating activities	-10 295	-9 710	-27 984
Cash flow from investment activities	0	0	-541
Cash flow from financing activities	0	0	0
Cash flow for the period	-10 295	-9 710	-28 525
Cash and cash equivalents at the beginning of the period	44 894	72 942	72 942
Exchange rate difference in cash and cash equivalents	230	116	477
Cash and cash equivalents at the end of the period	34 829	63 348	44 894

CHANGE OF EQUITY – THE GROUP

1/1-2022 - 31/12-2022

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2022)	1 748	1 068	106 608	-16 143	-18 937	74 344
Outline of previous year's results				-18 937	18 937	0
Registration of share issue	12	-1 068	1 056			0
Ongoing share Issue						
Translation difference				-2 756		-2 756
Allocation of staff warrants				1 216		1 216
The result of the period					-29 770	-29 770
At the end of the period (31/12-2022)	1 760	0	107 664	-36 620	-29 770	43 498

1/1-2023 - 31/3-2023

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2023)	1 760		107 664	-36 620	-29 770	43 034
Outline of previous year's results				-29 770	29 770	
Issue of warrants				208		208
Translation difference				11		11
The result of the period					-7 575	-7 575
At the end of the period (31/3-2023)	1 760		107 664	-66 171	-7 575	35 678

FINANCIAL OVERVIEW PARENT COMPANY

SUMMARY OF INCOME STATEMENT – PARENT COMPANY (KSEK)	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Operating income			
Net sales	0	0	0
Total operating income	0	0	0
Operating expenses			
Other external expenses	-344	-354	-1 796
Staff costs	-227	-304	-1 209
Total operating expenses	-571	-658	-3 005
Operating profit	-571	-658	-3 005
Financial posts	-124	-108	-50 491
Profit before tax	-695	-766	-53 496
Tax	0	0	0
The result of the period	-695	-766	-53 496

SUMMARY OF BALANCE SHEET – PARENT COMPANY (KSEK)	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Assets			
Fixed assets			
Financial assets	5 000	34 555	5 000
Total fixed assets	5 000	34 555	5 000
Current assets			
Receivables	10 470	412	510
Cash and bank balances	28 860	61 510	39 315
Total current assets	39 330	61 922	39 825
Total assets	44 330	96 477	44 825
Equity and liabilities			
Equity			
Share capital	1 760	1 760	1 760
Other contributed capital	111 864	111 864	111 864
Other equity	-69 046	-16 586	-15 758
Result of the period	-695	-766	-53 496
Total equity	43 883	96 272	44 370
Current liabilities			
Current liabilities	447	205	455
Total short-term liabilities	447	205	455
Total equity and liabilities	44 330	96 477	44 825

SUMMARY OF CASH FLOW
– PARENT COMPANY (KSEK)

	Q1 2023 1/1-31/3	Q1 2022 1/1-31/3	2022 1/1-31/12
Cash flow from operating activities	-455	-666	-2 861
Cash flow from investment activities	-10 000	-5 000	-25 000
Cash flow from financing activities	0	0	0
Cash flow for the period	0	-5 666	-27 861
Cash and cash equivalents at the beginning of the period	39 315	67 176	67 176
Cash and cash equivalents at the end of the period	28 860	61 510	39 315

CHANGE OF EQUITY – PARENT COMPANY

1/1-2022 - 31/12-2022

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2022)	1 748	1 068	110 808	-13 165	-3 809	96 650
Outline of previous year's results				-3 809	3 809	0
Registration of share issue	12	-1 068	1 056			0
Issue of warrants				1 216		1 216
The result of the period					-53 496	-766
At the end of the period (31/12-2022)	1 760	0	111 864	-15 758	-53 496	44 370

1/1-2023 – 31/3-2023

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2023)	1 760	0	111 864	-15 758	-53 496	44 370
Outline of previous year's results				-53 496	53 496	0
Issue of warrants				208		208
The result of the period					-695	-695
At the end of the period (31/3-2023)	1 760	0	111 864	-69 046	-695	43 883

THE POWER
OF PRECISION.
FOR EVERY
ONCOLOGIST.
TODAY.



2CUREX AB (publ)

Corporate registration number: **559128-0077**

2CUREX A/S

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark
Phone: +45 2211 5399 / E-mail: info@2curex.com
